-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $68

Benzinga·07/15/2025 13:11:33
Listen to the news
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $71 to $68.